Ribosome-Directed Therapies in Cancer

Creative Commons License

Temaj G., Chichiarelli S., Eufemi M., Altieri F., Hadziselimovic R., Farooqi A. A., ...Daha Fazla

BIOMEDICINES, cilt.10, sa.9, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 10 Sayı: 9
  • Basım Tarihi: 2022
  • Doi Numarası: 10.3390/biomedicines10092088
  • Dergi Adı: BIOMEDICINES
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Social Sciences Citation Index (SSCI), Scopus, BIOSIS, Directory of Open Access Journals
  • Anahtar Kelimeler: ribosome, cancer, target drugs, rRNA and tRNA inhibition, RNA-POLYMERASE I, PEPTIDYL TRANSFERASE CENTER, C-MYC, MEGESTROL-ACETATE, PROTEIN-SYNTHESIS, STRUCTURAL BASIS, PROSTATE-CANCER, NONCODING RNAS, TRANSLATIONAL CONTROL, INACTIVATING PROTEIN
  • İstanbul Üniversitesi Adresli: Evet

Özet

The human ribosomes are the cellular machines that participate in protein synthesis, which is deeply affected during cancer transformation by different oncoproteins and is shown to provide cancer cell proliferation and therefore biomass. Cancer diseases are associated with an increase in ribosome biogenesis and mutation of ribosomal proteins. The ribosome represents an attractive anti-cancer therapy target and several strategies are used to identify specific drugs. Here we review the role of different drugs that may decrease ribosome biogenesis and cancer cell proliferation.